Our findings suggested that TKI administration had a superior effect as a first line treatment on OS and PFS for patients with BMs from NSCLC, but the EGFR mutation status made no difference for OS and PFSI. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.